These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 31553572)

  • 1. Hyaluronic Acid-Antibody Fragment Bioconjugates for Extended Ocular Pharmacokinetics.
    Famili A; Crowell SR; Loyet KM; Mandikian D; Boswell CA; Cain D; Chan J; Comps-Agrar L; Kamath A; Rajagopal K
    Bioconjug Chem; 2019 Nov; 30(11):2782-2789. PubMed ID: 31553572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of Antibody Hydrodynamic Size to Vitreal Clearance Revealed through Rabbit Studies Using a Species-Matched Fab.
    Shatz W; Hass PE; Mathieu M; Kim HS; Leach K; Zhou M; Crawford Y; Shen A; Wang K; Chang DP; Maia M; Crowell SR; Dickmann L; Scheer JM; Kelley RF
    Mol Pharm; 2016 Sep; 13(9):2996-3003. PubMed ID: 27244474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration.
    Mordenti J; Cuthbertson RA; Ferrara N; Thomsen K; Berleau L; Licko V; Allen PC; Valverde CR; Meng YG; Fei DT; Fourre KM; Ryan AM
    Toxicol Pathol; 1999; 27(5):536-44. PubMed ID: 10528633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocular tissue distribution and pharmacokinetic study of a small 13kDa domain antibody after intravitreal, subconjuctival and eye drop administration in rabbits.
    Gough G; Szapacs M; Shah T; Clements P; Struble C; Wilson R
    Exp Eye Res; 2018 Feb; 167():14-17. PubMed ID: 29074387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein engineering to increase the potential of a therapeutic antibody Fab for long-acting delivery to the eye.
    Tesar D; Luoma J; Wyatt EA; Shi C; Shatz W; Hass PE; Mathieu M; Yi L; Corn JE; Maass KF; Wang K; Dion MZ; Andersen N; Loyet KM; van Lookeren Campagne M; Rajagopal K; Dickmann L; Scheer JM; Kelley RF
    MAbs; 2017; 9(8):1297-1305. PubMed ID: 28854082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocular Half-Life of Intravitreal Biologics in Humans and Other Species: Meta-Analysis and Model-Based Prediction.
    Caruso A; Füth M; Alvarez-Sánchez R; Belli S; Diack C; Maass KF; Schwab D; Kettenberger H; Mazer NA
    Mol Pharm; 2020 Feb; 17(2):695-709. PubMed ID: 31876425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration.
    Gaudreault J; Fei D; Rusit J; Suboc P; Shiu V
    Invest Ophthalmol Vis Sci; 2005 Feb; 46(2):726-33. PubMed ID: 15671306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye.
    Furrer E; Berdugo M; Stella C; Behar-Cohen F; Gurny R; Feige U; Lichtlen P; Urech DM
    Invest Ophthalmol Vis Sci; 2009 Feb; 50(2):771-8. PubMed ID: 18757508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of Monoclonal Antibody and Antibody Fragments in The Mouse Eye Following Intravitreal Administration.
    Bussing D; Li Y; Guo L; Verma A; Sullivan JM; Shah DK
    J Pharm Sci; 2023 Aug; 112(8):2276-2284. PubMed ID: 37062415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocular Pharmacokinetics of Therapeutic Antibodies Given by Intravitreal Injection: Estimation of Retinal Permeabilities Using a 3-Compartment Semi-Mechanistic Model.
    Hutton-Smith LA; Gaffney EA; Byrne HM; Maini PK; Gadkar K; Mazer NA
    Mol Pharm; 2017 Aug; 14(8):2690-2696. PubMed ID: 28631484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyaluronic acid coating of gold nanoparticles for intraocular drug delivery: Evaluation of the surface properties and effect on their distribution.
    Apaolaza PS; Busch M; Asin-Prieto E; Peynshaert K; Rathod R; Remaut K; Dünker N; Göpferich A
    Exp Eye Res; 2020 Sep; 198():108151. PubMed ID: 32721426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the Fc Region in the Vitreous Half-Life of Anti-VEGF Drugs.
    Joo K; Park SJ; Choi Y; Lee JE; Na YM; Hong HK; Park KH; Kim HM; Chung JY; Woo SJ
    Invest Ophthalmol Vis Sci; 2017 Aug; 58(10):4261-4267. PubMed ID: 28850637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Mechanistic Model of the Intravitreal Pharmacokinetics of Large Molecules and the Pharmacodynamic Suppression of Ocular Vascular Endothelial Growth Factor Levels by Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration.
    Hutton-Smith LA; Gaffney EA; Byrne HM; Maini PK; Schwab D; Mazer NA
    Mol Pharm; 2016 Sep; 13(9):2941-50. PubMed ID: 26726925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicted biological activity of intravitreal VEGF Trap.
    Stewart MW; Rosenfeld PJ
    Br J Ophthalmol; 2008 May; 92(5):667-8. PubMed ID: 18356264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization.
    Zhu Q; Ziemssen F; Henke-Fahle S; Tatar O; Szurman P; Aisenbrey S; Schneiderhan-Marra N; Xu X; ; Grisanti S
    Ophthalmology; 2008 Oct; 115(10):1750-5, 1755.e1. PubMed ID: 18708261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and characterization of an octameric PEG-protein conjugate system for intravitreal long-acting delivery to the back of the eye.
    Shatz W; Hass PE; Peer N; Paluch MT; Blanchette C; Han G; Sandoval W; Morando A; Loyet KM; Bantseev V; Booler H; Crowell S; Kamath A; Scheer JM; Kelley RF
    PLoS One; 2019; 14(6):e0218613. PubMed ID: 31251757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. sFlt Multivalent Conjugates Inhibit Angiogenesis and Improve Half-Life In Vivo.
    Altiok EI; Browne S; Khuc E; Moran EP; Qiu F; Zhou K; Santiago-Ortiz JL; Ma JX; Chan MF; Healy KE
    PLoS One; 2016; 11(6):e0155990. PubMed ID: 27257918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits.
    Gaudreault J; Fei D; Beyer JC; Ryan A; Rangell L; Shiu V; Damico LA
    Retina; 2007; 27(9):1260-6. PubMed ID: 18046235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin.
    Nguyen A; Reyes AE; Zhang M; McDonald P; Wong WL; Damico LA; Dennis MS
    Protein Eng Des Sel; 2006 Jul; 19(7):291-7. PubMed ID: 16621915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbit.
    Li H; Lei N; Zhang M; Li Y; Xiao H; Hao X
    Exp Eye Res; 2012 Apr; 97(1):154-9. PubMed ID: 21933673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.